A Phase III trial of SPN-810 (Molindone) for treating Impulsive Aggression in adolescents who have ADHD

Trial Profile

A Phase III trial of SPN-810 (Molindone) for treating Impulsive Aggression in adolescents who have ADHD

Planning
Phase of Trial: Phase III

Latest Information Update: 05 Mar 2018

At a glance

  • Drugs Molindone (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use
  • Sponsors Supernus Pharmaceuticals
  • Most Recent Events

    • 05 Mar 2018 New trial record
    • 27 Feb 2018 According to a Supernus Pharmaceuticals media release, this trial is anticipated to start in mid-2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top